FDA-approved
Heart & blood
Desirudin
Evidence
FDA approved
Class
Direct thrombin inhibitor (recombinant hirudin)
KEY TAKEAWAY
Desirudin is a recombinant form of hirudin, a 65-amino-acid anticoagulant first found in the saliva of medicinal leeches. It is sold as Iprivask. The FDA approved desirudin (Iprivask) in 2003 to prevent deep vein thrombosis after elective hip replacement.
Written by the Veylo editorial team · Updated
November 2026
What it is
Direct thrombin inhibitor (recombinant hirudin)
Approved for
Preventing deep vein thrombosis after hip replacement surgery
Key fact
The FDA approved desirudin (Iprivask) in 2003 to prevent deep vein thrombosis after elective hip replacement.
Route
Subcutaneous injection
Evidence strength
FDA approved
Desirudin is a recombinant form of hirudin, a 65-amino-acid anticoagulant first found in the saliva of medicinal leeches. It is sold as Iprivask.
It binds thrombin directly and blocks it, which prevents blood clots.
The FDA approved desirudin (Iprivask) in 2003 to prevent deep vein thrombosis after elective hip replacement.
Preventing deep vein thrombosis after hip replacement surgery.
Bleeding is the main risk. The label carries a boxed warning for spinal or epidural hematomas.
U.S. FDA prescribing information for Desirudin. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.